We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma

Christina L. Roland, MD1; Genevieve M. Boland, MD, PhD1,2; Elizabeth G. Demicco, MD3,4; Kristelle Lusby, MD5; Davis Ingram, BS5; Caitlin D. May, PhD5,6; Christine M. Kivlin, BS5,6; Kelsey Watson, BS1; Ghadah A. Al Sannaa, MD3; Wei-Lien Wang, MD3; Vinod Ravi, MD7; Raphael E. Pollock, MD, PhD8; Dina Lev, MD5,9; Janice N. Cormier, MD1; Kelly K. Hunt, MD1; Barry W. Feig, MD1; Alexander J. Lazar, MD, PhD3; Keila E. Torres, MD, PhD1
[+] Author Affiliations
1Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston
2Department of Surgery, Massachusetts General Hospital, Boston
3Department of Pathology, University of Texas MD Anderson Cancer Center, Houston
4Department of Pathology, Mount Sinai Hospital, New York, New York
5Sarcoma Research Center, University of Texas MD Anderson Cancer Center, Houston
6Graduate School of Biomedical Sciences, University of Texas Health Science Center at Houston
7Department of Medical Oncology, University of Texas MD Anderson Cancer Center, Houston
8Department of Surgery, Ohio State University, Columbus
9Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston
JAMA Surg. 2016;151(4):347-354. doi:10.1001/jamasurg.2015.4205.
Text Size: A A A
Published online

Importance  Vascular leiomyosarcomas are a rare subtype of leiomyosarcomas that most commonly affect the inferior vena cava and account for 5% of all leiomyosarcomas. These tumors are aggressive malignant tumors for which adjuvant modalities have not shown increased efficacy compared with surgery.

Objectives  To evaluate the outcomes of patients with vascular leiomyosarcoma and the association between vascular leiomyosarcomas and immunohistochemical molecular markers, to determine their potential prognostic and therapeutic utility.

Design, Setting, and Participants  Retrospective medical record review of a cohort of 77 patients who presented to the University of Texas MD Anderson Cancer Center in Houston during the period from January 1993 to April 2012. Data were analyzed during the period from November 2012 to May 2015. All of the patients received a confirmed diagnosis of vascular leiomyosarcoma. Immunohistochemical studies for biomarkers were performed on a tissue microarray that included 26 primary specimens of vascular leiomyosarcoma.

Main Outcomes and Measures  Demographic and clinical factors were evaluated to assess clinical course, patterns of recurrence, and survival outcomes for patients with primary vascular leiomyosarcoma. A univariate Cox proportional hazards model was used to correlate disease-specific survival and time to recurrence with potential prognostic indicators.

Results  Sixty-three patients with localized disease who underwent surgical resection formed the study population, and their data were used for subsequent outcomes analysis. The median age at diagnosis was 58 years (range, 22-78 years). The majority of patients were female (41 patients [65%]) and white (51 patients [81%]). The 5-year disease-specific survival rate after tumor resection was 65%. The median time to local recurrence was 43 months, the median time to distant recurrence was 25 months, and the median time to concurrent local and distant recurrences was 15 months (P = .04). Strong expressions of cytoplasmic β-catenin (hazard ratio, 5.33 [95% CI, 0.97-29.30]; P = .06) and insulinlike growth factor 1 receptor (hazard ratio, 2.74 [95% CI, 1.14-6.56]; P = .02) were associated with inferior disease-specific survival.

Conclusions and Relevance  Vascular leiomyosarcomas are aggressive malignant tumors, with high recurrence rates. Expressions of β-catenin and insulinlike growth factor 1 receptor were associated with poor disease-specific survival. Prospective studies should evaluate the clinical and therapeutic utility of these molecular markers.

Figures in this Article


Place holder to copy figure label and caption
Figure 1.
Kaplan-Meier Estimate of Time to Recurrence and Sarcoma-Specific Survival Stratified by Recurrence Type

DSS indicates disease-specific survival; vLMS, vascular leiomyosarcoma.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Kaplan-Meier Estimate of Time to Recurrence and Sarcoma-Specific Survival Stratified by Protein Expression Levels

DSS indicates disease-specific survival; IGF-1R, insulinlike growth factor 1 receptor.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles